Figure S5 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G₁–S Transition

Darolutamide suppresses the AR in NMRI nu/nu male mice effectively and safely. A-B: 16 NMRI nu/nu male mice subcutaneously bearing a PC346C tumor were treated for 14 days with 200 mg/kg darolutamide orally daily (n=4), 100 mg/kg darolutamide orally daily (n=4), were castrated and received vehicle (n=4) or were sham-castrated and received vehicle (n=4). Mean of prostate and seminal vesicle weight with SD is shown. *: p < 0.05; **: p < 0.01. C: Bodyweight of mice treated with darolutamide was not different from mice treated with vehicle, while bodyweight loss of castrated mice reached up to 5%, before recovery after 14 days.